N/A N=142 Preemptive Resuscitation for Eradication of Septic Shock
Sepsis · Severe Sepsis
Primary: Number of Participants With Worsening Organ System Dysfunction Defined by SOFA Score Increase ≥ 1 — 34; 20 Participants — p=0.064
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=106,629 Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care
Sepsis
Primary: Door-to-antibiotic Time — 160; 146; 139; 140 minutes — p=<0.001
N/A N=22 Piperacillin PK Analysis in Severe Sepsis Patients
Sepsis · Severe Sepsis
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 4 participants
N/A N=458 Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
Sepsis · Disease Progression · Septic Shock
Primary: Proportion of the Patients Who Require Vasopressor/Mechanical Ventilator — 53; 21 participants
Phase 2 N=120 Vitamin C & Thiamine to Treat Sepsis and Septic Shock
Sepsis · Septic Shock
Primary: Mortality Rates — 12; 7 Participants — p=0.344
Phase 3 N=125 Vitamin C and Septic Shock
Septic Shock · Sepsis
Primary: Number of Participants With ICU Mortality — 20; 14 Participants
Phase 3 N=252 Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock
Septic Shock
Primary: Efficacy and Safety of Dopamine Versus Norepinephrine in Septic Shock — 67; 51 participants
N/A N=15 PK Analysis of Piperacillin in Septic Shock Patients
Septic Shock
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 10 participants
Phase 3 N=18 Statin Therapy in the Treatment of Sepsis
Septic Shock
Primary: Time to Shock Reversal — 44.4; 28.6 hours
Phase 1 N=31 A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
Severe Sepsis
Primary: Percentage of Incidence Rates of Serious Adverse Events (SAEs), Adverse Events (AEs), Immune-mediated AEs, AEs Leading to Discontinuation, and Deaths — 6.7; 43.8; 93.3…
Phase 2 N=140 Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.
Sepsis, Severe · Septic Shock
Primary: Time to Vasopressor Independence (Hours) — 27; 53 hours — p=<0.001
Phase 3 N=1,696 Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
Sepsis
Primary: 28-Day All-Cause Mortality — 26.4; 24.2 percentage of participants — p=0.313
N/A N=450 Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Septic Shock · Endotoxemia
Primary: Mortality — 78; 84 Participants
Phase 2 N=1,379 GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
Phase 2 N=250 Rapid Administration of Carnitine in sEpsis
Septic Shock
Primary: Delta SOFA Score — -1.8; -0.34; -1.68; -2.15 units on a scale
N/A N=150 Fluid Responsiveness Evaluation in Sepsis-associated Hypotension
Sepsis · Hypotension
Primary: Fluid Balance — 0.65; 2.02 Liters — p=0.021
N/A N=30 A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)
Sepsis
Primary: ICU-free Days to 14 Days After Enrollment — 9; 11 days
Phase 2 N=88 Thiamine as a Metabolic Resuscitator in Septic Shock
Septic Shock
Primary: Lactate Level 24 Hours After the First Study Medication Dose — 2.6; 2.5 mmol/L — p=0.40
N/A N=1,351 Protocolized Care for Early Septic Shock
Sepsis · Severe Sepsis · Septic Shock
Primary: Hospital Mortality — 92; 81; 86 Participants
Phase 2 N=72 Citrulline in Severe Sepsis
Severe Sepsis · Acute Lung Injury
Primary: Vasopressor Dependency Index — 50.0; 44.4; 49.0 mmHg/catecholamine index — p=0.86
Phase 4 N=43 Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
Sepsis · Septic Shock
Primary: Cumulative Vasopressor Index (CVI) — 2.3; 3.0; -2.0; -1.4 units on a scale — p=0.238
N/A N=19 High MAP in Septic Shock With Hypertension
Septic Shock
Primary: Mean Arterial Pressure — 90 mmHg
N/A N=185 Algorithm for Predicting the Unfavorable Course of Sepsis in Children
Sepsis
Primary: Blood Leukocyte Subpopulations: the Absolute Numbers of Leukocytes of Specific Phenotypes — 16.0; 11.2; 11.9; 4.9 10^9 cells/l — p=<0.05
Phase 2 N=301 Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
Septic Shock
Primary: Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Mortality) — 63.1453; 63.1578; 64.5744; 63.9809 days
Phase 2 N=13 Acetyl-L-Carnitine in the Treatment of Septic Shock
Septic Shock
Primary: Mean Arterial Blood Pressure — 60; 60 mm Hg
Phase 3 N=30 Cholecalciferol Supplementation for Sepsis in the ICU
Hypovitaminosis D
Primary: Change in Vitamin D Status 5 Days Following Supplementation With Cholecalciferol — 19; 15; 17; 19 ng/mL
N/A N=120 Initiation of Hydrocortisone for the Treatment of Septic Shock
Septic Shock
Primary: 28-day Mortality — 19; 23 Participants
Phase 4 N=1,554 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial
Septic Shock
Primary: 90-day Mortality — 323; 329 Participants
Phase 2 N=84 HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients
Septic Shock
Primary: Time to Resolution of Shock — 89; 84 Hours
Phase 2 N=488 Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Acute Respiratory Distress Syndrome · Critical Illness · Respiratory Failure
Primary: Days Alive and Free of Organ Support to Day 28 — 20.2; 20.5; 19.7; 18.4 days — p=0.65